889 results on '"Récher, Christian"'
Search Results
2. Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study
3. Differential prognostic values of the three AKT isoforms in acute myeloid leukemia
4. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.
5. ATP1A1/BCL2L1 predicts the response of myelomonocytic and monocytic acute myeloid leukemia to cardiac glycosides
6. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
7. AML consolidation therapy: timing matters
8. Low frequency of Vγ9Vδ2 T cells predicts poor survival in newly diagnosed acute myeloid leukemia
9. Cost comparison of post-remission strategies in younger and older AML patients in France
10. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial
11. Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia
12. Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study
13. Vitamin C and D supplementation in acute myeloid leukemia
14. Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO
15. LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study
16. Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis
17. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial
18. Overlapping features of therapy-related and de novo NPM1-mutated AML
19. Mini-consolidations or intermediate-dose cytarabine (IDAC) for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.
20. Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study
21. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial
22. Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial
23. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries
24. Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
25. In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study
26. Outcomes in Critically Ill Allogeneic Hematopoietic Stem-Cell Transplantation Recipients.
27. Treatment of Relapsed and Refractory AML: Non-intensive Approach in Unfit Patients
28. Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML
29. Transplant in AML: just follow the NPM1 guide!
30. Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study.
31. Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in France
32. Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia
33. Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia
34. A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries
35. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study
36. Kidney Involvement in Patients With Chronic Myelomonocytic Leukemia or BCR-ABL–Negative Myeloproliferative Neoplasms
37. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
38. A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia
39. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort
40. Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signature
41. Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome
42. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial
43. Erythroblastic islands: A fertile ground for CD47 expression in myelodysplastic syndrome and acute erythroid leukaemia
44. Genomic landscape of hyperleukocytic acute myeloid leukemia
45. Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells
46. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
47. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy
48. Effective interaction in an unbalanced Fermion mixture
49. Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
50. The CARMEN-France registry of adult patients with immune thrombocytopenia and autoimmune hemolytic anemia in France
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.